Keryx Biopharmaceuticals — Q2 2018 Earnings Presentation
17 slides from Keryx Biopharmaceuticals's earnings presentation, Aug 8, 2018
Slide 1: Keryx 2Q18 Financial Results
KERYX 2Q18 Financial results August 8, 2018 Exhibit 99.2
Slide 2: Agenda
Agenda Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Opening Remarks Jodie Morrison, Interim CEO Business Highlights Scott Holmes, CFO Question & Answer All
Slide 3: Forward-Looking Statements
Forward-Looking Statements Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Some of the statements included in this presentation, particularly those regarding the commercialization of and demand for Auryxia, the asset-based revolving credit facility and the proposed merger with Akebia Therapeutics
Slide 4: Additional Information and Where to Find It
Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Additional Information and Where to Find It In connection with the proposed merger, Akebia and Keryx plan to file with the SEC and mail or otherwise provide to their respective stockholders a joint proxy statement/prospectus regarding the proposed t
Slide 5: Opening remarks
Opening remarks Jodie Morrison, Interim CEO
Slide 6: Second Quarter 2018 Business Highlights
Second Quarter 2018 Business Highlights Commercial progress Auryxia prescription demand doubled and revenue increased >70%compared to 2Q17 Growth from both hyperphosphatemia and iron deficiency anemia indications Market share* increased a full point in just 3 months Announced proposed merger with Ak
Slide 7: Creating a Leader in Kidney Disease Therapies
Creating a Leader in Kidney Disease Therapies Fully integrated Potential to maximize Auryxia sales Builds launch momentum for vadadustat in the U.S., subject to FDA approval Partner of choice for renal community 1. Hypoxia Inducible Factor - Prolyl Hydroxylase Inhibitor 2. Chronic Kidney Disease 3.
Slide 8: 2Q18 Business Highlights
2Q18 Business Highlights Scott Holmes, CFO
Slide 9: Second Quarter 2018 Revenue Growth
Second Quarter 2018 Revenue Growth Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Second Quarter 2018 Performance $24.1 million net U.S. Auryxia product sales 71% increase compared to 2Q17 Gross-to-net adjustment: 49%
Slide 10: Second Quarter 2018 Prescription and Market Share Growth
Second Quarter 2018 Prescription and Market Share Growth Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Second Quarter 2018 Performance ~42,500 Auryxia prescriptions, 101% growth over 2Q17 IMS/Specialty Mix: 59/41 Mix expected to shift to more IMS as Davita Rx closes its specialty pharmacy Table
Slide 11: Commercial Progress for the Auryxia Brand
Commercial Progress for the Auryxia Brand (compared to 2Q17) Copyright © 2018 by Keryx Biopharmaceuticals, Inc. ~2000Additional Auryxia prescribers 35% Increase in prescriptions per prescriber 100% Increase in prescriptions More Physicians Prescribing Auryxia Greater Depth of Prescribing Significant
Slide 12: Success Moving Physicians Along Adoption Curve
Success Moving Physicians Along Adoption Curve Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Sales Dynamics Significantly increased the number of high-prescribing physicians Expect to move more physicians along this adoption curve Clinical familiarity, broad formulary coverage and availability
Slide 13: Frequency of Contact and Samples Drive Prescribing
Frequency of Contact and Samples Drive Prescribing Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Drivers of Prescribing Continuous brand presence correlates to increased prescribing Samples are a leading indicator of prescribing behavior 80% of physician sampled in 1Q18 wrote an Auryxia prescri
Slide 14: Closing remarks
Closing remarks Jodie Morrison, Interim CEO
Slide 15: In Summary
In Summary Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Good progress commercially Prescriber base broadened Depth of prescribing increased Intend to build on current momentum to drive continued strong growth of Auryxia and create shareholder value Proposed merger with Akebia Therapeutics trac
Slide 16: Strong Foundation to Build a Leading Kidney Care Company
Strong Foundation to Build a Leading Kidney Care Company Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Phosphate Management Anemia Management Q&A Session
Slide 17: Keryx
KK KERYX X RMACEUTICALS,ING
Keryx Biopharmaceuticals — Q2 2018 Earnings Presentation on 6ix